Retrophin Inc (NASDAQ:RTRX) SVP Elizabeth E. Reed sold 1,050 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $17.73, for a total value of $18,616.50. Following the transaction, the senior vice president now directly owns 20,033 shares of the company’s stock, valued at approximately $355,185.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ RTRX traded up $0.01 during mid-day trading on Thursday, hitting $18.57. 591,400 shares of the company traded hands, compared to its average volume of 372,079. Retrophin Inc has a 1 year low of $17.53 and a 1 year high of $33.00. The company has a market cap of $740.47 million, a price-to-earnings ratio of -7.31 and a beta of 0.91. The company has a quick ratio of 4.52, a current ratio of 4.57 and a debt-to-equity ratio of 0.69.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.41). Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The company had revenue of $39.57 million for the quarter, compared to analysts’ expectations of $41.40 million. During the same period in the prior year, the company earned ($0.14) earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, sell-side analysts expect that Retrophin Inc will post -3.02 EPS for the current fiscal year.
Several research analysts recently weighed in on RTRX shares. ValuEngine cut Retrophin from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. TheStreet cut Retrophin from a “c-” rating to a “d+” rating in a research note on Friday, February 22nd. Barclays started coverage on Retrophin in a research note on Monday, April 22nd. They set an “overweight” rating and a $36.00 target price for the company. William Blair reaffirmed an “outperform” rating on shares of Retrophin in a research note on Wednesday, April 17th. Finally, BidaskClub cut Retrophin from a “hold” rating to a “sell” rating in a research note on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $45.67.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Retrophin Inc (RTRX) SVP Sells 1,050 Shares of Stock” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2019/05/16/insider-selling-retrophin-inc-rtrx-svp-sells-1050-shares-of-stock.html.
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Article: Are all No-Load Funds Equal?
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.